文拉法辛单药治疗锂盐单药治疗反应不佳的双相Ⅱ型抑郁患者。
Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy.
机构信息
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
出版信息
Acta Psychiatr Scand. 2010 Mar;121(3):201-8. doi: 10.1111/j.1600-0447.2009.01462.x. Epub 2009 Aug 19.
OBJECTIVE
We examine the safety and efficacy of venlafaxine monotherapy in bipolar type II (BP II) patients with major depressive episode (MDE) who were unresponsive to prior lithium monotherapy. We hypothesized that venlafaxine would be superior to lithium with a low hypomanic conversion rate.
METHOD
Seventeen patients who were unresponsive to prior lithium monotherapy were crossed to venlafaxine monotherapy for 12 weeks. The primary outcome was within-subject change in total Hamilton Depression Rating (HAM-D) score over time. Secondary outcomes included the change in Young Mania Rating (YMRS) and clinical global impressions severity (CGI/S) and change (CGI/C) scores.
RESULTS
Venlafaxine produced significantly greater reductions in HAM-D (P < 0.0005), CGI/S (P < 0.0005), and CGI/C (P < 0.0005) scores vs. prior lithium. There was no difference in mean YMRS scores between treatment conditions (P = 0.179).
CONCLUSION
Venlafaxine monotherapy may be a safe and effective monotherapy of BP II MDE with a low hypomanic conversion rate in lithium non-responders.
目的
我们研究了文拉法辛单药治疗对锂单药治疗无效的双相Ⅱ型（BP II）抑郁发作（MDE）患者的安全性和有效性。我们假设文拉法辛的疗效优于锂，且躁狂转化率较低。
方法
17 名对锂单药治疗无反应的患者交叉接受文拉法辛单药治疗 12 周。主要结局是 Hamilton 抑郁评定量表（HAM-D）总分随时间的变化。次要结局包括 Young 躁狂评定量表（YMRS）和临床总体印象严重程度（CGI/S）和变化（CGI/C）评分的变化。
结果
文拉法辛在 HAM-D（P < 0.0005）、CGI/S（P < 0.0005）和 CGI/C（P < 0.0005）评分方面的降低显著大于锂。两种治疗条件下的 YMRS 评分均值无差异（P = 0.179）。
结论
文拉法辛单药治疗可能是一种安全有效的治疗方法，对锂无反应的 BP II MDE 患者的躁狂转化率较低。
Zotero 插件